Liver transplantation is the sole curative option for HCC, but new therapies prompt reconsideration of transplant timing and ...

LIVER CANCER, the third leading cause of cancer-related deaths globally, is primarily attributed to hepatocellular carcinoma ...

The FDA has approved a ready-to-dilute, multi-dose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given the increased risk of death from cirrhosis-related complications in patients ...

A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

A study published in Nature Aging has revealed a promising new drug candidate that may help combat metabolic ...

An already approved cancer drug, Yervoy (ipilimumab), improved lung repair ability in a study of mice with idiopathic ...

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

During a Community Case Forum event, Stacey Stein, MD, discussed data guiding the use of current regimens for the treatment ...

RT-PCR test quantifying CP mRNA in blood can detect hepatocellular carcinoma early—especially in AFP-negative cases—offering ...